The anabolic effects of parathyroid hormone

Osteoporosis International

Volumn 13, Issue 4, 2002, Pages 267-277

  Rubin, M R ^a   Cosman, F ^a,c   Lindsay, R ^a,c   Bilezikian, J P ^a,b  

^a Department of Medicine ^*  (United States)

^b Columbia University ^*  (United States)

^c HELEN HAYES HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CONJUGATED ESTROGEN; ESTROGEN; GLUCOCORTICOID; PARATHYROID GLAND HORMONE; PARATHYROID HORMONE; PLACEBO;

BIOSYNTHESIS; CLINICAL TRIAL; ESTROGEN DEFICIENCY; FEMALE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OSSIFICATION; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW;

ANIMALS; BONE AND BONES; BONE DENSITY; FEMALE; HUMANS; HYPERPARATHYROIDISM; MALE; MODELS, ANIMAL; OSTEOPOROSIS; PARATHYROID HORMONE; RANDOMIZED CONTROLLED TRIALS;

EID: 0036250214     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200026     Document Type: Review

References (103)

1. Hyperparathyroidism: A common and polymorphic condition as illustrated by seventeen proven cases from one clinic
2. Skeletal disease in primary hyperparathyroidism
3. Anabolic actions of parathyroid hormone on bone
4. Characterization and evaluation of asymptomatic primary hyperparathyroidism
5. The histomorphometry of bone in primary hyperparathyroidism: Preservation of cancellous bone structure
6. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: Trabecular strut analysis
7. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women
8. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism
9. A comparison of bone structure and turnover in postmenopausal women with osteoporosis or primary hyperparathyroidism
10. Bone histomorphometry in hypoparathyroid patients treated with vitamin D
11. Fracture incidence in postmenopausal women with primary hyperparathyroidism
12. What is the clinical significance of bone loss in primary hyperparathyroidism?
13. The risk of hip fractures in patients with primary hyperparathyroidism: A population-based cohort study with a follow-up of 19 years
14. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures
15. Primary hyperparathyroidism and the risk of fracture: A population-based study
16. The pharmacology of estrogens in osteoporosis
17. Bisphosphonates: Mechanisms of action and clinical use
18. Calcitonin
19. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial
20. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
21. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial
22. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
23. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
24. Studies of calcium and phosphorous metabolism. V. A study of the bone trabeculae as a readily reversible supply of calcium
25. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis
26. Circadian variation in ionized calcium and intact parathyroid hormone: Evidence for sex differences in calcium homeostasis
27. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration
28. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone
29. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium
30. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide
31. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor
32. Pharmacological mechanisms of therapeutics: Parathyroid hormone
33. Dissociation of second messenger activation by parathyroid hormone fragments in osteosarcoma cells
34. PTH mechanism of action
35. Anabolic effects of PTH on bone
36. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa
37. Parathyroid hormone causes translocation of protein kinase-C from cytosol to membranes in rat osteosarcoma cells
38. Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: Exceptions that prove the rules
39. Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo
40. Analysis of gene expression by DNA microarray reveals novel clues to the mechanism of the catabolic and anabolic actions of PTH in bone
41. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures
42. Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats
43. Parathyroid hormone
44. Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture
45. PTH restores bone mass and enhances osteoblast IGF-1 gene expression in ovariectomized rats
46. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
47. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
48. Clinical review 114: Hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
49. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation
50. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene
51. Mechanisms of biphasic anabolic and catabolic effects of parathyroid hormone (PTH) on bone cells
52. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
53. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats
54. Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate
55. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys
56. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34)
57. Preliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis
58. Short-term effects of synthetic human parathyroid hormone administration on bone mineral metabolism in osteoporotic patients
59. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial
60. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human PTH fragment 1-34
61. Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients
62. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D
63. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol
64. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis
65. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride
66. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses
67. Human parathyroid peptide treatment of vertebral osteoporosis
68. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis
69. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover
70. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients
71. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients
72. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients
73. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: Increase in volumetric density y of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone
74. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency
75. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone a randomized controlled trial
76. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis
77. A randomized controlled multi-center study of 1-84 hPTH for treatment of postmenopausal osteoporosis
78. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
79. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
80. Insulin-like growth factor-I in men with idiopathic osteoporosis
81. Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men
82. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
83. Changes in bone markers predict bone accrual in osteoporotic men treated with parathyroid hormone
84. PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans
85. Parathyroid hormone (PTH 1-34) as a treatment for idiopathic osteoporosis in men: Changes in bone mineral density, bone markers and optimal duration of therapy
86. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study
87. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among post-menopausal women on oestrogen with osteoporosis
88. Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal
89. Two- and three-dimensional structural analysis of paired biopsies from osteoporotic patients before and after treatment with parathyroid hormone
90. Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis: Results from a placebo-controlled randomized trial
91. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial
92. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
93. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women
94. PTH bisphosphonates in the treatment of osteoporosis: Design of the PTH and alendronate (PaTH) trial
95. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery
96. Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism
97. Primary hyperparathyroidism: Changes in trabecular bone remodeling following surgical treatment: Evaluated by histomorphometric methods
98. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial
99. The post-PTH experience in men with idiopathic osteoporosis: Bisphosphonates vs non-pharmacologic therapy
100. Sequential parathyroid hormone/alendronate therapy for osteoporosis: Robbing Peter to pay Paul?
101. Effects of LY333334 [recombinant parathyroid hormone (1-34)] on cortical bone strength indices as assessed by peripheral quantitative computed tomography
102. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats